Ernexa Therapeutics, Inc. (ERNA)
1.79
-0.14
(-7.25%)
USD |
NASDAQ |
Nov 12, 16:00
1.80
+0.01
(+0.56%)
After-Hours: 20:00
Ernexa Therapeutics Free Cash Flow (Quarterly) : -3.17M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -3.17M |
| June 30, 2026 | -4.155M |
| March 31, 2026 | -2.266M |
| December 31, 2025 | -1.163M |
| September 30, 2025 | -1.294M |
| June 30, 2025 | -2.532M |
| March 31, 2025 | -2.065M |
| December 31, 2024 | -3.545M |
| September 30, 2024 | -6.304M |
| June 30, 2024 | -2.508M |
| March 31, 2024 | -3.848M |
| December 31, 2023 | -4.68M |
| September 30, 2023 | -5.826M |
| June 30, 2023 | -3.872M |
| March 31, 2023 | -6.049M |
| December 31, 2022 | -5.456M |
| September 30, 2022 | -6.159M |
| June 30, 2022 | -4.18M |
| March 31, 2022 | -5.478M |
| December 31, 2021 | -6.979M |
| September 30, 2021 | -6.429M |
| June 30, 2021 | -6.804M |
| March 31, 2021 | -3.43M |
| December 31, 2020 | -1.650M |
| September 30, 2020 | -2.407M |
| Date | Value |
|---|---|
| June 30, 2020 | -2.205M |
| March 31, 2020 | -1.878M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.147M |
| June 30, 2019 | 0.237M |
| March 31, 2019 | 0.384M |
| December 31, 2018 | 0.206M |
| September 30, 2018 | 0.012M |
| June 30, 2018 | 0.027M |
| March 31, 2018 | -0.492M |
| December 31, 2017 | -0.841M |
| September 30, 2017 | -2.167M |
| June 30, 2017 | 2.82M |
| March 31, 2017 | -0.715M |
| December 31, 2016 | -0.105M |
| September 30, 2016 | -0.259M |
| June 30, 2016 | 0.403M |
| March 31, 2016 | -0.681M |
| December 31, 2015 | -2.207M |
| September 30, 2015 | -1.565M |
| June 30, 2015 | -2.598M |
| March 31, 2015 | 0.558M |
| December 31, 2014 | -3.474M |
| September 30, 2014 | -2.042M |
| June 30, 2014 | -1.796M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Cerenome, Inc. | -7.631M |
| ACADIA Pharmaceuticals, Inc. | 10.26M |
| Alnylam Pharmaceuticals, Inc. | 271.15M |
| Anika Therapeutics, Inc. | 6.716M |
| Savara, Inc. | -42.82M |